Autologous cultured urological tissue cells - RegenMedTX

Drug Profile

Autologous cultured urological tissue cells - RegenMedTX

Alternative Names: Neo-Bladder Augment; Neo-bladder construct - RegenMedTX; Neo-Bladder Replacement; Neo-Urinary Conduit; Urinary neo-bladder construct

Latest Information Update: 24 Aug 2015

Price : $50

At a glance

  • Originator Tengion
  • Developer RegenMedTX; Tengion
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Genitourinary disorders
  • No development reported Neurogenic bladder

Most Recent Events

  • 01 Dec 2014 Tengion completes a phase I trial in Genitourinary disorders in USA (NCT01087697)
  • 01 Jan 2014 Tengion completes enrolment in its phase I trial for Genitourinary disorders in USA (NCT01087697)
  • 13 Nov 2012 Phase-I development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top